Last reviewed · How we verify
NCT05838950
HIIT Effects on Cardiometabolic Health
NA trial testing high-intensity interval training intervention in Obesity in 60 participants. Currently enrolling.
23 August 2025
Quick facts
| Lead sponsor | Syracuse University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 29 September 2023 |
| Primary completion | 23 August 2025 |
| Estimated completion | 10 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- high-intensity interval training intervention
Conditions studied
- Obesity — all drugs for Obesity →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Metabolic Disease — all drugs for Metabolic Disease →
- High-intensity Interval Training — all drugs for High-intensity Interval Training →
Sponsor
Syracuse University
Who can join
Adults 18 to 25, any sex, with Obesity or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this randomized clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group. HIIT-A, HIIT-B, and HIIT-C groups will participate in six sessions of a running based HIIT program over a 2-week training period. Pre-clinical markers of cardiovascular disease, blood lipids and fasting glucose will be measured at the following three time points: baseline, post-intervention, and 2 weeks after the training cessation (i.e., measure for detraining effect). All measurements will be performed three days before the training program and three days after the intervention to avoid the effect of the last training session. Afterwards, the detraining test will be measured 2 weeks post intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05838950
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Syracuse University trials
Trials by the same sponsor.
- NCT06698497 — Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance · NA · completed
- NCT05988515 — AI-Assisted Treatment for Residual Speech Sound Disorders · NA · recruiting
- NCT07215533 — Effects of HIIT vs. TRE on Type 2 Diabetes Risk · NA · recruiting
- NCT05929859 — Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders · Phase 1, PHASE2 · recruiting
- NCT05949060 — Effects of Self-Compassion Practice on Stress Reactivity Among Sexual Minority Women · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05838950 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Syracuse University
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05838950.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing